Zusammenfassung
Die Multiple Sklerose (MS) gilt traditionell als eine von T-Lymphozyten vermittelte Erkrankung. Allerdings spricht immer mehr für eine kritische Beteiligung von B-Lymphozyten und Autoantikörpern am pathologischen Geschehen bei der MS. Somit liegt es nahe, gegen B-Zellen gerichtete Therapieansätze zu verfolgen. In dieser Arbeit werden zunächst die für eine Schlüsselrolle der B-Zellen bei der Immunpathologie der MS sprechenden Erkenntnisse zusammengefasst und anschließend die Datenlage zur Anwendung von Atacicept, einer neuen B-Lymphozyten-gerichteten Therapiemöglichkeit bei MS, vorgestellt und kritisch gewürdigt. Bei Atacicept handelt es sich um ein humanes rekombinantes Fusionsprotein, das unter anderem aus demjenigen Teil eines bestimmten Rezeptors besteht, an den die Zytokine BLyS („B-lymphocyte stimulator“) und APRIL („A proliferation-inducing ligand“) andocken. BlyS und APRIL sind wichtige Regulatoren der Reifung, Funktion und Überlebensdauer von B-Zellen. Atacicept zeigt selektive Wirkungen auf bestimmte Zellen der B-Lymphozyten-Zellreihe. So wirkt Atacicept auf reife B-Zellen und blockiert Plasmazellen sowie späte Stadien der B-Zell-Entwicklung, während die B-Lymphozyten-Vorläuferzellen und Gedächtnis-B-Zellen unbeeinflusst bleiben. Bereits nachgewiesen sind die Wirksamkeit von Atacicept in Tiermodellen von Autoimmunerkrankungen und die biologische Aktivität von Atacicept bei Patienten mit systemischem Lupus erythematodes (SLE) und rheumatoider Arthritis (RA). In derzeit laufenden klinischen Studien werden Sicherheit, Verträglichkeit und Wirksamkeit von Atacicept bei Patienten mit MS, SLE und RA untersucht.
Summary
Multiple sclerosis (MS) has traditionally been considered to be a T cell-mediated disease. However, there is an increasing body of evidence for the involvement of B cells and autoantibodies in the pathology of this disease, providing a rationale for treatment strategies directed against B cells. This paper summarizes the evidence for a key role of B cells in the immunopathology of MS and reviews data supporting the use of a novel B cell-targeted therapy, atacicept, for this condition. Atacicept is a human recombinant fusion protein that comprises the binding portion of a receptor for both BLyS (B Lymphocyte Stimulator) and APRIL (A PRoliferation-Inducing Ligand), two cytokines that have been identified as important regulators of B cell maturation, function and survival. Atacicept has shown selective effects on cells of the B cell lineage, acting on mature B cells and blocking plasma cells and late stages of B cell development while sparing B cell progenitors and memory cells. The efficacy of atacicept in animal models of autoimmune disease and the biological activity of atacicept in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) has been demonstrated. Ongoing clinical studies are investigating the safety, tolerability and efficacy of atacicept in patients with MS, SLE and RA.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00115-009-2838-6/MediaObjects/115_2009_2838_Fig1_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00115-009-2838-6/MediaObjects/115_2009_2838_Fig2_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00115-009-2838-6/MediaObjects/115_2009_2838_Fig3_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00115-009-2838-6/MediaObjects/115_2009_2838_Fig4_HTML.gif)
Literatur
Lassmann H, Bruck W, Lucchinetti CF (2007) The immunopathology of multiple sclerosis: an overview. Brain Pathol 17:210–218
Kornek B et al (2000) Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 157:267–276
Lucchinetti C et al (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707–717
Marrie RA (2004) Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol 3:709–718
Hohlfeld R, Wekerle H (2004) Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci U S A 101 [Suppl 2]:14599–14606
Willer CJ, Dyment DA, Risch NJ et al (2003) Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci U S A 100:12877–12882
Barcellos LF et al (2003) HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 72:710–716
Poser CM (2006) The multiple sclerosis trait and the development of multiple sclerosis: genetic vulnerability and environmental effect. Clin Neurol Neurosurg 108:227–233
Sospedra M, Martin R (2005) Immunology of multiple sclerosis. Annu Rev Immunol 23:683–747
Chitnis T (2007) The role of CD4 T cells in the pathogenesis of multiple sclerosis. Int Rev Neurobiol 79:43–72
Hemmer B, Nessler S, Zhou D et al (2006) Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol 2:201–211
Delgado S, Sheremata WA (2006) The role of CD4+ T-cells in the development of MS. Neurol Res 28:245–249
Hemmer B, Archelos JJ, Hartung HP (2002) New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 3:291–301
Medana I, Martinic MA, Wekerle H, Neumann H (2001) Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am J Pathol 159:809–815
McDole J, Johnson AJ, Pirko I (2006) The role of CD8+ T-cells in lesion formation and axonal dysfunction in multiple sclerosis. Neurol Res 28:256–261
Chofflon M (2005) Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach? BioDrugs 19:299–308
Brown BA, Kantesaria PP, McDevitt LM (2007) Fingolimod: a novel immunosuppressant for multiple sclerosis. Ann Pharmacother 41:1660–1668
Hemmer B, Hartung HP (2007) Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Ann Neurol 62:314–326
Cree B (2006) Emerging monoclonal antibody therapies for multiple sclerosis. Neurologist 12:171–178
CAMMS223 Trial Investigators et al (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359:1786–1801
Zeyda M et al (2005) Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum 52:2730–2739
Simpson BS, Coles AJ (2007) Rationale for cytotoxic monoclonal antibodies in MS. Int MS J 14:48–56
Genovese MC et al (2008) Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 58:2652–2661
Hagenbeek A et al (2008) First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 111:5486–5495
Silverman GJ (2006) Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms. Arthritis Rheum 54:2356–2367
Liossis SN, Sfikakis PP (2008) Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol 127:280–285
Hawker K (2008) B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data. Curr Opin Neurol 21 [Suppl 1]:19–25
Zouali MB (2008) Lymphocytes–chief players and therapeutic targets in autoimmune diseases. Front Biosci 13:4852–4861
Svensson L et al (2002) A comparative analysis of B cell-mediated myelin oligodendrocyte glycoprotein-experimental autoimmune encephalomyelitis pathogenesis in B cell-deficient mice reveals an effect on demyelination. Eur J Immunol 32:1939–1946
Owens GP, Bennett JL, Gilden DH, Burgoon MP (2006) The B cell response in multiple sclerosis. Neurol Res 28:236–244
Cepok S et al (2005) Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 128:1667–1676
Gilden DH et al (2001) Molecular immunologic strategies to identify antigens and B-cell responses unique to multiple sclerosis. Arch Neurol 58:43–48
Qin Y et al (2003) Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis. Lab Invest 83:1081–1088
Archelos JJ, Storch MK, Hartung HP (2000) The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol 47:694–706
Franciotta D, Salvetti M, Lolli F et al (2008) B cells and multiple sclerosis. Lancet Neurol 7:852–858
Villar LM et al (2005) Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 115:187–194
Perini P, Ranzato F, Calabrese M et al (2006) Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis. J Neurol Neurosurg Psychiatry 77:953–955
Prineas JW, Graham JS (1981) Multiple sclerosis: cap** of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann Neurol 10:149–158
Scolding NJ et al (1989) Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature 339:620–622
Serafini B, Rosicarelli B, Magliozzi R et al (2004) Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14:164–174
Magliozzi R et al (2007) Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130:1089–1104
MacKay F, Tangye SG (2004) The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers. Curr Opin Pharmacol 4:347–354
Dillon SR, Gross JA, Ansell SM, Novak AJ (2006) An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 5:235–246
Krumbholz M et al (2005) BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201:195–200
Thangarajh M, Masterman T, Hillert J et al (2007) A proliferation-inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis. Scand J Immunol 65:92–98
Thangarajh M, Gomes A, Masterman T et al (2004) Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis. J Neuroimmunol 152:183–190
Thangarajh M et al (2005) Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis. J Neuroimmunol 167:210–214
Weinshenker BG et al (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46:878–886
Hauser SL et al (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676–688
Keegan M et al (2005) Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366:579–582
Zettl UK et al (2006) Lesion pathology predicts response to plasma exchange in secondary progressive MS. Neurology 67:1515–1516
Stüve O et al (2005) Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol 62:1620–1623
Stüve O et al (2009) Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis. Arch Neurol 66:259–261
Kerschensteiner M et al (1999) Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 189:865–870
Gross JA et al (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404:995–999
Schneider P et al (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189:1747–1756
Marsters SA et al (2000) Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 10:785–788
Roschke V et al (2002) BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 169:4314–4321
Yan M et al (2001) Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol 2:638–643
Seshasayee D et al (2003) Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 18:279–288
Castigli E et al (2005) TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 201:35–39
Castigli E et al (2005) TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 37:829–834
Hsu BL, Harless SM, Lindsley RC et al (2002) Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 168:5993–5996
Thompson JS et al (2001) BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293:2108–2111
Dillon SR et al (2008) BLyS/APRIL heterotrimers activate human B cells, are elevated in SLE and RA patient sera, and are neutralized by atacicept (abstr 760). Arthritis Rheum 58:A17–A3278
Benson MJ et al (2008) Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 180:3655–3659
Gross JA et al (2001) TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity 15:289–302
Munafo A, Priestley A, Nestorov I et al (2007) Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol 63:647–656
Dall’Era M et al (2007) Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 56:4142–4150
Tak PP et al (2008) Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 58:61–72
Heffernan J et al (2008) The evaluation of atacicept on protective immunity in the mouse streptococcal host resistance model (abstr 1934). Toxicol Sci 102:398
MacKay F et al (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190:1697–1710
Do RK et al (2000) Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 192:953–964
Varfolomeev E et al (2004) APRIL-deficient mice have normal immune system development. Mol Cell Biol 24:997–1006
Carbonatto M et al (2008) Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept. Toxicol Sci 105:200–210
Nestorov I, Munafo A, Papasouliotis O, Visich J (2008) Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J Clin Pharmacol 48:406–417
Anolik J, Sanz IB (2004) B cells in human and murine systemic lupus erythematosus. Curr Opin Rheumatol 16:505–512
Martinez-Gamboa L, Brezinschek HP, Burmester GR, Dorner T (2006) Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy. Autoimmun Rev 5:437–442
Kalled SL (2005) The role of BAFF in immune function and implications for autoimmunity. Immunol Rev 204:43–54
Huntington ND et al (2006) A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses. Int Immunol 18:1473–1485
Lewis K et al (2008) Atacicept inhibits disease in multiple forms of experimental autoimmune encephalomyelitis. Mult Scler 14 [Suppl 1]:78(P168)
Plitz T et al (2008) Design of a four-arm, randomized, placebo-controlled phase II study of weeks of atacicept monotherapy in relapsing multiple sclerosis. Mult Scler 14 [Suppl 1]:173(P493)
Sergott RC et al (2008) Design of an exploratory, two-arm, randomized, placebo-controlled Phase II study of 36 weeks of atacicept treatment in patients with optic neuritis as clinically isolated syndrome. Mult Scler 14 [Suppl 1]:177(P508)
Fisher JB et al (2006) Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 113:324–332
Gordon-Lipkin E et al (2007) Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology 69:1603–1609
Frohman E et al (2006) Optical coherence tomography in multiple sclerosis. Lancet Neurol 5:853–863
Danksagung
Der Autor bedankt sich bei Frau Dr. Andrea Plant PhD (Caudex Medical) für die technische Hilfe bei der Erstellung des Manuskripts, Herrn Dr. Norbert Zessack, MerckSerono für die kritische Durchsicht sowie Herrn PD Dr. Patrick Küry für die Hilfe bei der Erstellung der Abbildungen.
Interessenkonflikt
Der Autor hat nach Genehmigung durch den Rektor der HHU Honorare für Beratungen und Vortragstätigkeit von BayerScheringPharma; Biogen Idec; Bio MS; Genzyme; Merck Serono; Novartis; Teva Sanofi Aventis erhalten.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hartung, HP. Atacicept bei Multipler Sklerose. Nervenarzt 80, 1462–1472 (2009). https://doi.org/10.1007/s00115-009-2838-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00115-009-2838-6